These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 24689054)

  • 1. Aberrant glycosylation as biomarker for cancer: focus on CD43.
    Tuccillo FM; de Laurentiis A; Palmieri C; Fiume G; Bonelli P; Borrelli A; Tassone P; Scala I; Buonaguro FM; Quinto I; Scala G
    Biomed Res Int; 2014; 2014():742831. PubMed ID: 24689054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycans as cancer biomarkers.
    Adamczyk B; Tharmalingam T; Rudd PM
    Biochim Biophys Acta; 2012 Sep; 1820(9):1347-53. PubMed ID: 22178561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein.
    de Laurentiis A; Gaspari M; Palmieri C; Falcone C; Iaccino E; Fiume G; Massa O; Masullo M; Tuccillo FM; Roveda L; Prati U; Fierro O; Cozzolino I; Troncone G; Tassone P; Scala G; Quinto I
    Mol Cell Proteomics; 2011 May; 10(5):M111.007898. PubMed ID: 21372249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Characterizing Cancer Glycans with Lectin-Based Analytical Methods.
    Pearson AJ; Gallagher ES
    Methods Mol Biol; 2019; 1928():389-408. PubMed ID: 30725466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant glycosylation associated with enzymes as cancer biomarkers.
    Meany DL; Chan DW
    Clin Proteomics; 2011 Jun; 8(1):7. PubMed ID: 21906357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.
    Ho WL; Hsu WM; Huang MC; Kadomatsu K; Nakagawara A
    J Hematol Oncol; 2016 Sep; 9(1):100. PubMed ID: 27686492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycosylation Changes in Brain Cancer.
    Veillon L; Fakih C; Abou-El-Hassan H; Kobeissy F; Mechref Y
    ACS Chem Neurosci; 2018 Jan; 9(1):51-72. PubMed ID: 28982002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques.
    Haga Y; Ueda K
    Glycoconj J; 2022 Apr; 39(2):303-313. PubMed ID: 35156159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of mucin-type O-glycosylation (MTOG) induced by peracetyl N-thioglycolyl-d-galactosamine (Ac
    Dwivedi V; Saini P; Tasneem A; Agarwal K; Sampathkumar SG
    Biochem Biophys Res Commun; 2018 Nov; 506(1):60-65. PubMed ID: 30336974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycan-specific antibodies as potential cancer biomarkers: a focus on microarray applications.
    Tikhonov A; Smoldovskaya O; Feyzkhanova G; Kushlinskii N; Rubina A
    Clin Chem Lab Med; 2020 Sep; 58(10):1611-1622. PubMed ID: 32324152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death.
    Hernandez JD; Nguyen JT; He J; Wang W; Ardman B; Green JM; Fukuda M; Baum LG
    J Immunol; 2006 Oct; 177(8):5328-36. PubMed ID: 17015718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosylation: a hallmark of cancer?
    Vajaria BN; Patel PS
    Glycoconj J; 2017 Apr; 34(2):147-156. PubMed ID: 27975160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated CD43 glycoforms as target of immunotherapy.
    Tuccillo FM; Palmieri C; Fiume G; de Laurentiis A; Schiavone M; Falcone C; Iaccino E; Galandrini R; Capuano C; Santoni A; D'Armiento FP; Arra C; Barbieri A; Dal Piaz F; Venzon D; Bonelli P; Buonaguro FM; Scala I; Mallardo M; Quinto I; Scala G
    Mol Cancer Ther; 2014 Mar; 13(3):752-62. PubMed ID: 24356816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer glycan epitopes: biosynthesis, structure and function.
    Pearce OMT
    Glycobiology; 2018 Sep; 28(9):670-696. PubMed ID: 29546349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of glyco-biomakers and glycan profiles in cancer stem cells.
    Pujari R; Dubey SK
    Glycobiology; 2024 Apr; 34(6):. PubMed ID: 36864577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.
    Chugh S; Gnanapragassam VS; Jain M; Rachagani S; Ponnusamy MP; Batra SK
    Biochim Biophys Acta; 2015 Dec; 1856(2):211-25. PubMed ID: 26318196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoproteins in the Sera of Oncological Patients.
    Hernychová L; Uhrík L; Nenutil R; Novotný MV
    Klin Onkol; 2019; 32(Supplementum 3):39-45. PubMed ID: 31627705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.
    Thomas D; Rathinavel AK; Radhakrishnan P
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188464. PubMed ID: 33157161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lectin biosensors in cancer glycan biomarker detection.
    Silva MLS
    Adv Clin Chem; 2019; 93():1-61. PubMed ID: 31655728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer.
    Cornelissen LA; Van Vliet SJ
    Biomolecules; 2016 May; 6(2):. PubMed ID: 27153100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.